Use of risk chart algorithms for the identification of psoriatic arthritis patients at high risk for cardiovascular disease: findings derived from the project CARMA cohort after a 7.5-year follow-up period

Autor: Jesús Tornero, Alba Erra, Santos Castañeda, Carolina Pérez-García, Raimon Sanmartí, Sara Marsal, Ingrid Moller, Esperanza Naredo, Miguel A González-Gay, Celia Erausquin, Ivan Castellví, Javier Llorca, Alejandro Muñoz, María Galindo, Enrique Raya, Lydia Abasolo, Gema Bonilla, Alfonso Corrales, Inmaculada Ureña, Carlos Rodríguez-Lozano, Carlos González-Juanatey, Cristina Fernandez Carballido, Francisco J López-Longo, Miguel Ángel González-Gay, Eduardo Collantes, José A Miranda-Filloy, Sagrario Bustabad, Indalecio Monteagudo, Jose A Piqueras, Tatiana Cobo, Joan Maymó, Carmen Barbadillo, Soledad Ojeda, Jaime Calvo Alen, Antonio Fernandez Nebro, Isabel Rodríguez, Pilar Font, Martina Steiner, Eugenio Chamizo Carmona, Beatriz González Álvarez, Santiago Munoz, Joan M Nolla, Fernando Sánchez-Alonso, Julio Sanchez, Raul Menor Almagro, Ana Pérez Gómez, Monica Ibañez, Elena Heras-Recuero, Trinidad Pérez Sandoval, Miren Uriarte-Ecenarro, Angela Pecondón, Hye Sang Park, Jessica Polo y La Borda, Zulema Plaza, Carmen García Gómez, Ivan Ferraz-Amaro, Jesús Tomás Sanchez-Costa, Olga Carmen Sánchez-González, Ana Isabel Turrión-Nieves, Ana Perez-Alcalá, José L FernándezSueiro, José A Pinto-Tasende, Eugenia Gonzálezde Rábago, María J González-Fernández, Ramón Huguet Codina, Beatriz Yoldi, Mercedes Ramentol, Gabriela Ávila, Cayetano Alegre, Fernando Gamero, José García Torón, María P Moreno-Gil, Antonio Juan-Mas, Pilar Espiño, Inmaculada Ros, Horacio Berman, Oscar Fontseré Patón, Benjamín Fernández Gutiérrez, José M Pina-Salvador, María D Fábregas, Montserrat Romera, Jesús A García-Vadillo, Rosario García de Vicuña, María A Belmonte, María V Irigoyen, Olga Martínez González, Rebeca Belmonte Gómez, Pastora Granados Bautista, Azucena Hernández Sanz, José Santos Rey, Carmen O Sánchez-González, Javier Bachiller, Antonio Zea, Francisco J Manero, Chesús Beltrán Audera, Marta Medrano, Jesús Babío Herráez, Javier del Pino, Ruth López González, María Enriqueta Peiró, José M Senabre, José C Rosas, Isabel Rotés, Estefanía Moreno, Javier Calvo, Amalia Rueda, Pilar Morales, Ana Nieto, Ana Ruibal Escribano, Sergio Ros Expósito, Ginés Sánchez Nievas, Enrique Júdez Navarro, Manuela Sianes Fernández, Silvia Martínez Pardo, Manel Pujol, Alberto Cantabrana, Esmeralda Delgado, Sergio Rodríguez Montero, Javier Rivera Redondo, Teresa González Hernández, Francisco J González-Polo, José M Moreno, Emilio Giner Serret, Laura Cebrián Méndez, María Teresa Navío, Teresa Pedraz Penalva, Encarnación Pagán, Pablo Mesadel Castillo, Ana Cruz, Ana Turrión, Desireé Ruíz, Antonio López Meseguer, Manuel J Moreno, Luis F Linares, Mercedes Morcillo, María L González-Gómez, José M Aramburu, Natalia A Rivera, Olaia Fernández Berrizbeitia, Manel Riera, Yolanda María León, Miriam Amirall, Jordi Fiter, Julia Fernández Melón, Luis Espadaler, Joaquín Belzunegui, Inmaculada Bañegil, César Díaz, Ramón Valls, María Bonet, Eva Revuelta Evrard, Javier R Godo, José A González-Fernández

Publikováno v: RMD Open, Vol 10, Iss 2 (2024)

Objective To assess the predictive value of four cardiovascular (CV) risk algorithms for identifying high-risk psoriatic arthritis (PsA) patients.Methods Evaluation of patients with PsA enrolled in the Spanish prospective project CARdiovascular in Rh

Externí odkaz: https://doaj.org/article/24b10d2acb8442f4903aa568a7fb12ad

Impact of IL6R genetic variants on treatment efficacy and toxicity response to sarilumab in rheumatoid arthritis

Autor: Luis Sainz, Pau Riera, Patricia Moya, Sara Bernal, Jordi Casademont, Cesar Díaz-Torné, Ana Milena Millán, Hye Sang Park, Adriana Lasa, Hector Corominas

Publikováno v: Arthritis Research & Therapy, Vol 25, Iss 1, Pp 1-10 (2023)

Abstract Background Sarilumab, an IL-6 receptor antagonist, is a first-line biologic disease-modifying anti-rheumatic drug for rheumatoid arthritis. The identification of genetic biomarkers as predictors of response to sarilumab could allow for a per

Externí odkaz: https://doaj.org/article/0444fe7ddf56436ab6f8401650ec4da3

Altered CD39 and CD73 Expression in Rheumatoid Arthritis: Implications for Disease Activity and Treatment Response

Autor: María Angels Ortiz, Cesar Diaz-Torné, Juan Jose De Agustin, Paula Estrada, Delia Reina, María Victoria Hernandez, Hye Sang, Carlos Zamora, Elisabet Cantó, Hector Corominas, Silvia Vidal

Publikováno v: Biomolecules, Vol 14, Iss 1, p 1 (2023)

In rheumatoid arthritis (RA) synovium, ATP, and ADP are released, sparking inflammation. Ectoenzymes CD39 and CD73 metabolize these purine nucleotides, generating anti-inflammatory adenosine. Therefore, dysregulated CD39 and CD73 expression may impac

Externí odkaz: https://doaj.org/article/02ad33378fba483cba27ae8913a31b9a

Severe Disease in Patients With Recent-Onset Psoriatic Arthritis. Prediction Model Based on Machine Learning

Autor: Rubén Queiro, Daniel Seoane-Mato, Ana Laiz, Eva Galindez Agirregoikoa, Carlos Montilla, Hye Sang Park, Jose A. Pinto Tasende, Juan José Bethencourt Baute, Beatriz Joven Ibáñez, Elide Toniolo, Julio Ramírez, Cristina Pruenza García-Hinojosa

Publikováno v: Frontiers in Medicine, Vol 9 (2022)

ObjectivesTo identify patient- and disease-related characteristics that make it possible to predict higher disease severity in recent-onset PsA.MethodsWe performed a multicenter observational prospective study (2-year follow-up, regular annual visits

Externí odkaz: https://doaj.org/article/2ca224e3c0ab4dd7993bc8c45bc901a2

Role of IL6R Genetic Variants in Predicting Response to Tocilizumab in Patients with Rheumatoid Arthritis

Autor: Luis Sainz, Pau Riera, Patricia Moya, Sara Bernal, Jordi Casademont, Cesar Díaz-Torné, Ana Milena Millán, Hye Sang Park, Adriana Lasa, Héctor Corominas

Publikováno v: Pharmaceutics, Vol 14, Iss 9, p 1942 (2022)

Rheumatoid arthritis (RA) is a prevalent autoimmune disease characterized by chronic arthritis that may lead to irreversible joint damage and significant disability. Patients with RA are commonly treated with Tocilizumab (TCZ), an IL-6 receptor (IL-6

Externí odkaz: https://doaj.org/article/c77ef964cf5745659f5d71f8609ecbda